Diet-induced alteration of microbiota and development of obesity, nonalcoholic fatty liver disease and diabetes

Diet-induced alteration of microbiota and development of obesity, nonalcoholic fatty liver disease and diabetes - DIAMOND trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47711

Enrollment

228

Registered

2015-11-10

Start date

2016-02-09

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes insulin resistance

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: BMI > 40 kg/m2 or > 35 kg/m2 with comorbidities Undergoing a laparoscopic gastric bypass Age between 18 and 65;Control population: BMI between 20-25 kg/m2 Indication for laparoscopic cholecystectomy Indication for gastroscopy Age 18 to 65 years

Exclusion criteria

Exclusion criteria: Both groups: Type 1 diabetes Alcohol abuse or drug abuse Inflammatory illness, such as auto-immune disease Degenerative disease Physician prescribed use of corticosteroids and prednisone;Controlgroup Diabetes type 2 Cachexia

Design outcomes

Primary

Measure	Time frame
* Bodyweight, BMI, abdominal circumference, plasma glucose/insulin, lipidspectrum * Faecal and intestinal microbiota composition * Plasma en faecal Short Chain Fatty Acids, Glucagon-like-peptide-1 * Paneth cel typing by determination of luminal en faecal concentrations of lysozym/HD5/HD6/LL-37/sPLA2/HIP/PAP * Intestinal protein en mRNA expression and localisation of lysozym/HD5/HD6 * Mucus typing by determination of the number of goblet cells, mucin 2 protein concentration en glycosylation. * Volatile Organic Compounds (VOC) in exhailed air * Fecal calprotectin in obese subjects	—

Measure

Time frame

* Bodyweight, BMI, abdominal circumference, plasma glucose/insulin, lipidspectrum * Faecal and intestinal microbiota composition * Plasma en faecal Short Chain Fatty Acids, Glucagon-like-peptide-1 * Paneth cel typing by determination of luminal en faecal concentrations of lysozym/HD5/HD6/LL-37/sPLA2/HIP/PAP * Intestinal protein en mRNA expression and localisation of lysozym/HD5/HD6 * Mucus typing by determination of the number of goblet cells, mucin 2 protein concentration en glycosylation. * Volatile Organic Compounds (VOC) in exhailed air * Fecal calprotectin in obese subjects

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results